Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB-Reference-Cited by-同舟云学术

Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB

Published:2024-02-21 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Fróes Renata de Sá Brito^ORCID,Andrade Adriana Ribas^ORCID,Faria Mikaell Alexandre Gouvea^ORCID,de Souza Heitor Siffert Pereira^ORCID,Parra Rogério Serafim^ORCID,Zaltman Cyrla^ORCID,dos Santos Carlos Henrique Marques^ORCID,Bafutto Mauro^ORCID,Quaresma Abel Botelho^ORCID,Santana Genoile Oliveira^ORCID,Luporini Rafael Luís^ORCID,de Lima Junior Sérgio Figueiredo^ORCID,Miszputen Sender Jankiel^ORCID,de Souza Mardem Machado^ORCID,Herrerias Giedre Soares Prates^ORCID,Junior Roberto Luiz Kaiser^ORCID,do Nascimento Catiane Rios^ORCID,Féres Omar^ORCID,de Barros Jaqueline Ribeiro^ORCID,Sassaki Ligia Yukie^ORCID,Saad-Hossne Rogerio^ORCID

Abstract

AbstractThe Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) established a national registry of inflammatory bowel disease (IBD). The aim of the study was to identify clinical factors associated with disease severity in IBD patients in Brazil. A population-based risk model aimed at stratifying the severity of IBD based on previous hospitalization, use of biologics, and need for surgery for ulcerative colitis (UC) and Crohn’s Disease (CD) and on previous complications for CD. A total of 1179 patients (34.4 ± 14.7y; females 59%) were included: 46.6% with UC, 44.2% with CD, and 0.9% with unclassified IBD (IBD-U). The time from the beginning of the symptoms to diagnosis was 3.85y. In CD, 41.2% of patients presented with ileocolic disease, 32% inflammatory behavior, and 15.5% perianal disease. In UC, 46.3% presented with extensive colitis. Regarding treatment, 68.1%, 67%, and 47.6% received biological therapy, salicylates and immunosuppressors, respectively. Severe disease was associated with the presence of extensive colitis, EIM, male, comorbidities, and familial history of colorectal cancer in patients with UC. The presence of Montreal B2 and B3 behaviors, colonic location, and EIM were associated with CD severity. In conclusion, disease severity was associated with younger age, greater disease extent, and the presence of rheumatic EIM.

Funder

Brazilian Organization for Crohn's Disease and Colitis - GEDIIB

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-54332-1.pdf

Reference50 articles.

1. Kaplan, G. G. & Ng, S. C. Understanding and Preventing the global increase of inflammatory bowel disease. Gastroenterology 152(2), 313-321.e. https://doi.org/10.1053/j.gastro.2016.10.020 (2017).

2. da Luz, M. A. et al. Geosocial features and loss of biodiversity underlie variable rates of inflammatory bowel disease in a large developing country: A population-based study. Inflamm. Bowel Dis. 28(11), 1696–1708. https://doi.org/10.1093/ibd/izab346 (2022).

3. Quaresma, A. B. et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. Lancet Reg. Health Am. 9(13), 100298. https://doi.org/10.1016/j.lana.2022.100298 (2022).

4. Kaplan, G. G. & Windsor, J. W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18(1), 56–66. https://doi.org/10.1038/s41575-020-00360-x (2021).

5. Quaresma, A. B., Kaplan, G. G. & Kotze, P. G. The globalization of inflammatory bowel disease: The incidence and prevalence of inflammatory bowel disease in Brazil. Curr. Opin. Gastroenterol. 35(4), 259–264. https://doi.org/10.1097/MOG.0000000000000534 (2019).